

Nucleotide sequences which code for the lysR3 gene

Abstract

The present invention relates to polynucleotides corresponding to the lysR3 gene and which encode a LysR3 transcriptional regulator, methods of producing L-amino acids, and methods of screening for polynucleotides which encode proteins having LysR3 transcriptional regulator activity.

Inventors: **Moeckel, Bettina; (Duesseldorf, DE) ; Kreutzer, Caroline; (Melle, DE)**

Correspondence Name and Address: **OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA
VA
22314
US**

Assignee Name and Address: **DEGUSSA AG
Rodenbacher Chaussee 4
Hanau-Wolfgang
DE
D-63457**

Serial No.: **867537**

Series Code: **09**

Filed: **December 11, 2001**

U.S. Current Class:

435/252.3

U.S. Class at Publication:

435/252.3

Intern'l Class:

C12N 001/20

Foreign Application Data

Date	Code	Application Number
Aug 10, 2000	DE	100 39 049.8

Claims

1. An isolated polynucleotide which encodes a protein comprising the amino acid sequence of SEQ ID NO:2.
2. The isolated polynucleotide of claim 1, wherein said protein has LysR3 transcriptional regulatory activity.
3. An isolated polynucleotide, which comprises SEQ ID NO:1.
4. An isolated polynucleotide which is complementary to the polynucleotide of claim 3.
5. An isolated polynucleotide which is at least 70% identical to the polynucleotide of claim 3.
6. An isolated polynucleotide which is at least 80% identical to the polynucleotide of claim 3.
7. An isolated polynucleotide which is at least 90% identical to the polynucleotide of claim 3.
8. An isolated polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3; wherein said stringent conditions comprise washing in 5.times.SSC at a temperature from 50 to 68.degree. C.
9. The isolated polynucleotide of claim 3, which encodes a protein having LysR3 transcriptional regulatory activity.
10. An isolated polynucleotide which comprises at least 15 consecutive nucleotides of the polynucleotide of claim 3.
11. The isolated polynucleotide of claim 10 which comprises SEQ ID NO:3.
12. A vector comprising the isolated polynucleotide of claim 1.

13. A vector comprising the isolated polynucleotide of claim 3.
14. A host cell comprising the isolated polynucleotide of claim 1.
15. A host cell comprising the isolated polynucleotide of claim 3.
16. The host cell of claim 14, which is a Coryneform bacterium.
17. The host cell of claim 15, which is a Coryneform bacterium.
18. The host cell of claim 14, wherein said host cell is selected from the group consisting of Coryneform glutamicum, Corynebacterium acetoglutamicum, Corynebacterium acetoacidophilum, Corynebacterium melassecola, Corynebacterium thermoaminogenes, Brevibacterium flavum, Brevibacterium lactofermentum, Brevibacterium divaricatum.
19. The host cell of claim 14, wherein said host cell is selected from the group consisting of Coryneform glutamicum ATCC13032, Corynebacterium acetoglutamicum ATCC15806, Corynebacterium acetoacidophilum ATCC13870, Corynebacterium melassecola ATCC17965, Corynebacterium thermoaminogenes FERM BP-1539, Brevibacterium flavum ATCC14067, Brevibacterium lactofermentum ATCC13869, Brevibacterium divaricatum ATCC14020.
20. The host cell of claim 15, wherein said host cell is selected from the group consisting of Coryneform glutamicum, Corynebacterium acetoglutamicum, Corynebacterium acetoacidophilum, Corynebacterium melassecola, Corynebacterium thermoaminogenes, Brevibacterium flavum, Brevibacterium lactofermentum, Brevibacterium divaricatum.
21. The host cell of claim 15, wherein said host cell is selected from the group consisting of Coryneform glutamicum ATCC13032, Corynebacterium acetoglutamicum ATCC15806, Corynebacterium acetoacidophilum ATCC13870, Corynebacterium melassecola ATCC17965, Corynebacterium thermoaminogenes FERM BP-1539, Brevibacterium flavum ATCC14067, Brevibacterium lactofermentum ATCC13869, Brevibacterium divaricatum ATCC14020.
22. A Coryneform bacterium which comprises an attenuated *lysR3* gene.
23. The Coryneform bacterium of claim 22, wherein said *lysR3* gene comprises the polynucleotide sequence of SEQ ID NO:1.
24. The Coryneform bacterium of claim 27, wherein said *lysR3* gene comprises the polynucleotide sequence of SEQ ID NO:3.
25. Coryneform glutamicum DSM 13618.
26. A process for producing L-amino acids comprising culturing a bacterial cell in a medium suitable for producing L-amino acids, wherein said bacterial cell comprises an attenuated *lysR3* gene.
27. The process of claim 26, wherein said bacterial cell is a Coryneform bacterium or Brevibacterium.
28. The process of claim 26, wherein said bacterial cell is selected from the group consisting of Coryneform glutamicum, Corynebacterium acetoglutamicum, Corynebacterium acetoacidophilum, Corynebacterium melassecola, Corynebacterium thermoaminogenes, Brevibacterium flavum, Brevibacterium lactofermentum, Brevibacterium divaricatum.
29. The process of claim 26, wherein said bacterial cell is selected from the group consisting of Coryneform glutamicum ATCC13032, Corynebacterium acetoglutamicum ATCC15806, Corynebacterium acetoacidophilum ATCC13870, Corynebacterium melassecola ATCC17965, Corynebacterium thermoaminogenes FERM BP-1539, Brevibacterium flavum ATCC14067, Brevibacterium lactofermentum ATCC13869, Brevibacterium divaricatum ATCC14020.
30. The process of claim 26, wherein said *lysR3* gene comprises the polynucleotide sequence of SEQ ID NO:1.
31. The process of claim 26, wherein said *lysR3* gene comprises the polynucleotide sequence of SEQ ID NO:3.
32. The process of claim 26, wherein said L-amino acid is L-lysine.
33. The process of claim 32, wherein said bacterial cell is selected from the group consisting of Corynebacterium glutamicum FERM-P1709, Brevibacterium flavum FERM-P1708, Brevibacterium lactofermentum FERM-P1712, Corynebacterium glutamicum FERM-P6463, Corynebacterium glutamicum FERM-P6464, Corynebacterium glutamicum DM58-1, Corynebacterium glutamicum DG52-5, Corynebacterium glutamicum DSM 5714, and Corynebacterium glutamicum DSM 12866.
34. The process of claim 26, wherein said L-amino acid is L-valine.
35. The process of claim 33, wherein said bacterial cell is selected from the group consisting of Corynebacterium glutamicum DSM-12455, Corynebacterium glutamicum FERM-P 9324, Brevibacterium lactofermentum FERM-P9324, and Brevibacterium lactofermentum FERM-BP 1763.
36. The process of claim 32, wherein said bacteria further comprises at least one gene whose expression is enhanced, wherein said gene is selected from the group consisting of *dapA*, *eno*, *zwf*, *pyc*, and *lysE*.
37. The process of claim 32, wherein said bacteria further comprises at least one gene whose expression is attenuated, wherein said gene is selected from the group consisting of *pck*, *pgi*, and *poxB*.
38. The process of claim 26, wherein said bacteria further comprises at least one gene whose expression is enhanced, wherein said gene is selected from the group consisting of *ilvBN*, *ilvD* and *mqo*.
39. A process for screening for polynucleotides which encode a protein having *LysR3* transcriptional regulatory activity comprising hybridizing the isolated polynucleotide of claim 1 to the polynucleotide to be screened; expressing the polynucleotide to produce a protein; and detecting the presence

or absence of LysR3 transcriptional regulatory activity in said protein.

40. A process for screening for polynucleotides which encode a protein having LysR3 transcriptional regulatory activity comprising hybridizing the isolated polynucleotide of claim 3 to the polynucleotide to be screened; expressing the polynucleotide to produce a protein; and detecting the presence or absence of LysR3 transcriptional regulatory activity in said protein.

41. A method for detecting a nucleic acid with at least 70% homology to nucleotide of claim 1, comprising contacting a nucleic acid sample with a probe or primer comprising at least 15 consecutive nucleotides of the nucleotide sequence of claim 1, or at least 15 consecutive nucleotides of the complement thereof.

42. A method for producing a nucleic acid with at least 70% homology to nucleotide of claim 1, comprising contacting a nucleic acid sample with a primer comprising at least 15 consecutive nucleotides of the nucleotide sequence of claim 1, or at least 15 consecutive nucleotides of the complement thereof.

43. A method for detecting a nucleic acid with at least 70% homology to nucleotide of claim 3, comprising contacting a nucleic acid sample with a probe or primer comprising at least 15 consecutive nucleotides of the nucleotide sequence of claim 3, or at least 15 consecutive nucleotides of the complement thereof.

44. A method for producing a nucleic acid with at least 70% homology to nucleotide of claim 3, comprising contacting a nucleic acid sample with a primer comprising at least 15 consecutive nucleotides of the nucleotide sequence of claim 3, or at least 15 consecutive nucleotides of the complement thereof.

45. A method for making LysR3 protein, comprising: culturing the host cell of claim 14 for a time and under conditions suitable for expression of LysR3 protein, and collecting the LysR3 protein.

46. A method for making LysR3 protein, comprising: culturing the host cell of claim 15 for a time and under conditions suitable for expression of LysR3 protein, and collecting the LysR3 protein.

Description

CROSS-REFERENCE TO RELATED APPLICATION

[0001] The present application claims priority to German Application No. DE 10039049.8 filed Aug. 10, 2000, the entire contents of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

[0002] 1. Field of the Invention

[0003] The invention provides nucleotide sequences from Coryneform bacteria which code for the lysR3 gene and a process for the fermentative preparation of amino acids, in particular L-lysine and L-valine, by attenuation of the lysR3 gene. The lysR3 gene codes for the LysR3 protein, which is a transcription regulator of the LysR family.

[0004] 2. Discussion of the Background

[0005] L-Amino acids, in particular L-lysine and L-valine, are used in human medicine and in the pharmaceuticals industry, in the foodstuffs industry and very particularly in animal nutrition.

[0006] It is known that amino acids are prepared by fermentation from strains of Coryneform bacteria, in particular *Corynebacterium glutamicum*. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as, for example, stirring and supply of oxygen, or the composition of the nutrient media, such as, for example, the sugar concentration during the fermentation, or the working up to the product form by, for example, ion exchange chromatography, or the intrinsic output properties of the microorganism itself.

[0007] Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites or are auxotrophic for metabolites of regulatory importance and which produce amino acids are obtained in this manner.

[0008] Methods of the recombinant DNA technique have also been employed for some years for improving the strain of *Corynebacterium* strains which produce L-amino acids.

[0009] However, there remains a critical need for improved methods of producing L-amino acids and thus for the provision of strains of bacteria producing higher amounts of L-amino acids. On a commercial or industrial scale even small improvements in the yield of L-amino acids, or the efficiency of their production, are economically significant. Prior to the present invention, it was not recognized that attenuation of lysR3 gene encoding the a LysR3 transcriptional regulation protein would improve L-amino acid yields.

SUMMARY OF THE INVENTION

[0010] One object of the present invention, is providing a new process adjuvant for improving the fermentative production of L-amino acids, particularly L-lysine and L-glutamate. Such process adjuvants include enhanced bacteria, preferably enhanced Coryneform bacteria which express attenuated amounts of LysR3 transcriptional regulator which is encoded by the lysR3 gene.

[0011] Thus, another object of the present invention is providing such a bacterium, which expresses an attenuated amount of LysR3 transcriptional regulator or gene products of the lysR3 gene.

[0012] Another object of the present invention is providing a bacterium, preferably a Coryneform bacterium, which expresses a polypeptide that has an attenuated LysR3 transcriptional regulator activity. Another object of the invention is to provide a nucleotide sequence encoding a polypeptide which has LysR3 transcriptional regulator sequence. One embodiment of such a sequence is the nucleotide sequence of SEQ ID NO: 1.

[0013] A further object of the invention is a method of making LysR3 transcriptional regulator or an isolated polypeptide having a LysR3 transcriptional regulator activity, as well as use of such isolated polypeptides in the production of amino acids. One embodiment of such a polypeptide is the polypeptide having the amino acid sequence of SEQ ID NO: 2.

[0014] Other objects of the invention include methods of detecting nucleic acid sequences homologous to SEQ ID NO: 1, particularly nucleic acid sequences encoding polypeptides that have LysR3 transcriptional regulator activity, and methods of making nucleic acids encoding such polypeptides.

[0015] The above objects highlight certain aspects of the invention. Additional objects, aspects and embodiments of the invention are found in the following detailed description of the invention.

BRIEF DESCRIPTION OF THE DRAWING

[0016] FIG. 1: Map of the plasmid pCR2.1lysR3int.

DETAILED DESCRIPTION OF THE INVENTION

[0017] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art of molecular biology. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described herein. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

[0018] Reference is made to standard textbooks of molecular biology that contain definitions and methods and means for carrying out basic techniques, encompassed by the present invention. See, for example, Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1982) and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1989) and the various references cited therein.

[0019] Where L-amino acids or amino acids are mentioned in the following, this means one or more amino acid, including their salts, chosen from the group consisting of L-asparagine, L-threonine, L-serine, L-glutamate, L-glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan and L-arginine. L-Lysine is particularly preferred.

[0020] When L-lysine or lysine are mentioned in the following, not only the bases but also the salts, such as e.g. lysine monohydrochloride or lysine sulfate, are meant by this.

[0021] The invention provides an isolated polynucleotide from coryneform bacteria, comprising a polynucleotide sequence which codes for the lysR3 gene, chosen from the group consisting of

[0022] a) polynucleotide which is identical to the extent of at least 70% to a polynucleotide which codes for a polypeptide which comprises the amino acid sequence of SEQ ID No. 2,

[0023] b) polynucleotide which codes for a polypeptide which comprises an amino acid sequence which is identical to the extent of at least 70% to the amino acid sequence of SEQ ID No. 2,

[0024] c) polynucleotide which is complementary to the polynucleotides of a) or b), and

[0025] d) polynucleotide comprising at least 15 successive nucleotides of the polynucleotide sequence of a), b) or c) the polypeptide preferably having the activity of the transcription regulator LysR3.

[0026] The invention also provides the above-mentioned polynucleotide, this preferably being a DNA which is capable of replication, comprising:

[0027] (i) the nucleotide sequence shown in SEQ ID No.1 or

[0028] (ii) at least one sequence which corresponds to sequence (i) within the range of the degeneration of the genetic code, or

[0029] (iii) at least one sequence which hybridizes with the sequences complementary to sequences (i) or (ii), and optionally

[0030] (iv) sense mutations of neutral function in (i).

[0031] The invention also provides:

[0032] a DNA which is capable of replication and comprises the nucleotide sequence as shown in SEQ ID No.1;

[0033] a polynucleotide which codes for a polypeptide which comprises the amino acid sequence as shown in SEQ ID No. 2;

[0034] a vector containing the polynucleotide according to the invention, point d, in particular pCR2.1lysR3int, deposited in Escherichia coli DSM 13618 at the DSMZ [German Collection of Microorganisms and Cell Cultures], Braunschweig (Germany);

[0035] and Coryneform bacteria which contain an insertion or deletion in the lysR3 gene, in particular using the vector pCR2.1lysR3int.

[0036] The invention also provides polynucleotides which substantially comprise a polynucleotide sequence, which are obtainable by screening by means of hybridization of a corresponding gene library, which comprises the complete gene with the polynucleotide sequence corresponding to SEQ ID No. 1, with a probe which comprises the sequence of the polynucleotide mentioned, according to SEQ ID No. 1 or a fragment thereof, and isolation of the DNA sequence mentioned.

[0037] Polynucleotide sequences according to the invention are suitable as hybridization probes for RNA, cDNA and DNA, in order to isolate, in the full length, nucleic acids or polynucleotides or genes which code for the LysR3 protein or to isolate those nucleic acids or polynucleotides or genes which have a high similarity with the sequence of the lysR3 gene.

[0038] Polynucleotide sequences according to the invention are furthermore suitable as primers with the aid of which DNA of genes which code for the LysR3 protein can be prepared with the polymerase chain reaction (PCR).

[0039] Such oligonucleotides which serve as probes or primers comprise at least 30, preferably at least 20, very particularly preferably at least 15 successive nucleotides. Oligonucleotides which have a length of at least 40 or 50 nucleotides are also suitable.

[0040] "Isolated" means separated out of its natural environment.

[0041] "Polynucleotide" in general relates to polyribonucleotides and polydeoxyribonucleotides, it being possible for these to be non-modified RNA or DNA or modified RNA or DNA.

[0042] "Polypeptides" are understood as meaning peptides or proteins which comprise two or more amino acids bonded via peptide bonds.

[0043] The polypeptides according to the invention include a polypeptide according to SEQ ID No. 2, in particular those with the biological activity of the LysR3 protein, and also those which are at least 70%, preferably at least 80% and in particular at least 90% to 95% identical to the polypeptide according to SEQ ID No. 2 and have the activity mentioned.

[0044] The invention moreover provides a process for the fermentative preparation of amino acids, in particular L-lysine and L-valine, using Coryneform bacteria which in particular already produce amino acids, and in which the nucleotide sequences which code for the lysR3 gene are attenuated, in particular eliminated or expressed at a low level.

[0045] The term "attenuation" in this connection describes the reduction or elimination of the intracellular activity of one or more enzymes (proteins) in a microorganism which are coded by the corresponding DNA, for example by using a weak promoter or using a gene or allele which codes for a corresponding enzyme with a low activity or inactivates the corresponding gene or enzyme (protein), and optionally combining these measures.

[0046] The microorganisms which the present invention provides can prepare amino acids, in particular L-lysine and L-valine, from glucose, sucrose, lactose, fructose, maltose, molasses, starch, cellulose or from glycerol and ethanol. They can be representatives of Coryneform bacteria, in particular of the genus *Corynebacterium*. Of the genus *Corynebacterium*, there may be mentioned in particular the species *Corynebacterium glutamicum*, which is known among experts for its ability to produce L-amino acids.

[0047] Suitable strains of the genus *Corynebacterium*, in particular of the species *Corynebacterium glutamicum* (*C. glutamicum*), are in particular the known wild-type strains

[0048] *Corynebacterium glutamicum* ATCC13032

[0049] *Corynebacterium acetoglutamicum* ATCC15806

[0050] *Corynebacterium acetoacidophilum* ATCC13870

[0051] *Corynebacterium melassecola* ATCC17965

[0052] *Corynebacterium thermoaminogenes* FERM BP-1539

[0053] *Brevibacterium flavum* ATCC14067

[0054] *Brevibacterium lactofermentum* ATCC13869 and

[0055] *Brevibacterium divaricatum* ATCC14020

[0056] or L-amino acid-producing mutants or strains prepared therefrom, such as, for example, the L-lysine-producing strains

[0057] *Corynebacterium glutamicum* FERM-P 1709

[0058] *Brevibacterium flavum* FERM-P 1708

[0059] *Brevibacterium lactofermentum* FERM-P 1712

[0060] *Corynebacterium glutamicum* FERM-P 6463

[0061] *Corynebacterium glutamicum* FERM-P 6464

[0062] *Corynebacterium glutamicum* DM58-1

[0063] *Corynebacterium glutamicum* DG52-5

[0064] *Corynebacterium glutamicum* DSM 5714 and

[0065] *Corynebacterium glutamicum* DSM 12866

[0066] or such as, for example, the L-valine-producing strains

[0067] *Corynebacterium glutamicum* DSM 12455

[0068] *Corynebacterium glutamicum* FERM-P 9325

[0069] *Brevibacterium lactofermentum* FERM-P 9324

[0070] *Brevibacterium lactofermentum* FERM-BP 1763.

[0071] Preferably, a bacterial strain with attenuated expression of a *lysR3* gene that encodes a polypeptide with *LysR3* transcriptional regulation activity will improve amino acid yield at least 1%.

[0072] The inventors have succeeded in isolating the new *lysR3* gene of *C. glutamicum* which codes for the *LysR3* protein, which is a transcription regulator of the *LysR* family. To isolate the *lysR3* gene or also other genes of *C. glutamicum*, a gene library of this microorganism is first set up in *Escherichia coli* (*E. coli*). The setting up of gene libraries is described in generally known textbooks and handbooks. The textbook by Winnacker: *Gene und Klone, Eine Einführung in die Gentechnologie* [Genes and Clones, An Introduction to Genetic Engineering] (Verlag Chemie, Weinheim, Germany, 1990), or the handbook by Sambrook et al.: *Molecular Cloning, A Laboratory Manual* (Cold Spring Harbor Laboratory Press, 1989) may be mentioned as an example. A well-known gene library is that of the *E. coli* K-12 strain W3110 set up in λ vectors by Kohara et al. (*Cell* 50, 495-508 (1987)). Bathe et al. (*Molecular and General Genetics*, 252:255-265, 1996) describe a gene library of *C. glutamicum* ATCC13032, which was set up with the aid of the cosmid vector SuperCos I (Wahl et al., 1987, *Proceedings of the National Academy of Sciences USA*, 84:2160-2164) in the *E. coli* K-12 strain NM554 (Raleigh et al., 1988, *Nucleic Acids Research* 16:1563-1575). Bormann et al. (*Molecular Microbiology* 6(3), 317-326) (1992) in turn describe a gene library of *C. glutamicum* ATCC13032 using the cosmid pHc79 (Hohn and Collins, 1980, *Gene* 11, 291-298).

[0073] To prepare a gene library of *C. glutamicum* in *E. coli* it is also possible to use plasmids such as pBR322 (Bolivar, 1979, *Life Sciences*, 25, 807-818) or pUC9 (Vieira et al., 1982, *Gene*, 19:259-268). Suitable host are, in particular, those *E. coli* strains which are restriction- and recombination-defective, such as, for example, the strain DH5.alpha. (Jeffrey H. Miller: "A Short Course in Bacterial Genetics, A Laboratory Manual and Handbook for *Escherichia coli* and Related Bacteria", Cold Spring Harbour Laboratory Press, 1992).

[0074] The long DNA fragments cloned with the aid of cosmids or other λ -vectors can then be subcloned in turn into the usual vectors suitable for DNA sequencing.

[0075] Methods of DNA sequencing are described, inter alia, by Sanger et al. (*Proceedings of the National Academy of Sciences of the United States of America USA*, 74:5463-5467, 1977).

[0076] The resulting DNA sequences can then be investigated with known algorithms or sequence analysis programs, such as e.g. that of Staden (*Nucleic Acids Research* 14, 217-232(1986)), that of Marck (*Nucleic Acids Research* 16, 1829-1836 (1988)) or the GCG-program of Butler (*Methods of Biochemical Analysis* 39, 74-97 (1998)).

[0077] The new DNA sequence of *C. glutamicum* which codes for the *lysR3* gene and which, as SEQ ID No. 1, is a constituent of the present invention has been found in this manner. The amino acid sequence of the corresponding protein has furthermore been derived from the present DNA sequence by the methods described above. The resulting amino acid sequence of the *lysR3* gene product is shown in SEQ ID No. 2.

[0078] Coding DNA sequences which result from SEQ ID No. 1 by the degeneracy of the genetic code are also a constituent of the invention. In the same way, DNA sequences which hybridize with SEQ ID No. 1 or parts of SEQ ID No. 1 are a constituent of the invention. Conservative amino acid exchanges, such as e.g. exchange of glycine for alanine or of aspartic acid for glutamic acid in proteins, are furthermore known among experts as "sense mutations" which do not lead to a fundamental change in the activity of the protein, i.e. are of neutral function. It is furthermore known that changes on the N and/or C terminus of a protein cannot substantially impair or can even stabilize the function thereof. Information in this context can be found by the expert, inter alia, in Ben-Bassat et al. (*Journal of Bacteriology* 169:751-757 (1987)), in O'Regan et al. (*Gene* 77:237-251 (1989)), in Sahin-Toth et al. (*Protein Sciences* 3:240-247 (1994)), in Hochuli et al. (*Bio/Technology* 6:1321-1325 (1988)) and in known textbooks of genetics and molecular biology. Amino acid sequences which result in a corresponding manner from SEQ ID No. 2 are also a constituent of the invention.

[0079] Finally, DNA sequences which are prepared by the polymerase chain reaction (PCR) using primers which result from SEQ ID No. 1 are a constituent of the invention. Such oligonucleotides typically have a length of at least 15 nucleotides.

[0080] Instructions for identifying DNA sequences by means of hybridization can be found by the expert, inter alia, in the handbook "The DIG System Users Guide for Filter Hybridization" from Boehringer Mannheim GmbH (Mannheim, Germany, 1993) and in Liebl et al. (*International Journal of Systematic Bacteriology* 41: 255-260 (1991)). Instructions for amplification of DNA sequences with the aid of the polymerase chain reaction (PCR) can be found by the expert, inter alia, in the handbook by Gait: *Oligonukleotide [sic] synthesis: A Practical Approach* (IRL Press, Oxford, UK, 1984) and in Newton and Graham: *PCR* (Spektrum Akademischer Verlag, Heidelberg, Germany, 1994).

[0081] In the work on the present invention, it has been found that *Coryneform* bacteria produce amino acids, in particular L-lysine and L-valine, in an improved manner after attenuation of the *lysR3* gene.

[0082] To achieve an attenuation, either the expression of the *lysR3* gene or the catalytic properties of the enzyme protein can be reduced or eliminated. The two measures can optionally be combined.

[0083] The reduction in gene expression can take place by suitable culturing or by genetic modification (mutation) of the signal structures of gene expression. Signal structures of gene expression are, for example, repressor genes, activator genes, operators, promoters, attenuators, ribosome binding sites, the start codon and terminators. The expert can find information on this e.g. in the patent application WO 96/15246, in Boyd and Murphy (*Journal of Bacteriology* 170: 5949 (1988)), in Voskuil and Chambliss (*Nucleic Acids Research* 26: 3548 (1998)), in Jensen and Hammer (*Biotechnology and Bioengineering* 58: 191 (1998)), in Ptek et al. (*Microbiology* 142: 1297 (1996)), Vasicova et al. (*Journal of Bacteriology* 181: 6188 (1999)) and in known textbooks of genetics and molecular biology, such as e.g. the textbook by Knippers ("Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995) or that by Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 1990).

[0084] Mutations which lead to a change or reduction in the catalytic properties of enzyme proteins are known from the prior art; examples which may be mentioned are the works by Qiu and Goodman (*Journal of Biological Chemistry* 272: 8611-8617 (1997)), Sugimoto et al. (*Bioscience Biotechnology and Biochemistry* 61: 1760-1762 (1997)) and Mockel ("Die Threonindehydratase aus *Corynebacterium glutamicum*: Aufhebung der allosterischen Regulation und Struktur des Enzyms [Threonine dehydratase from *Corynebacterium glutamicum*: Cancelling the allosteric regulation

and structure of the enzyme]", Reports from the Julich Research Centre, Jul-2906, ISSN09442952, Julich, Germany, 1994). Summarizing descriptions can be found in known textbooks of genetics and molecular biology, such as e.g. that by Hagemann ("Allgemeine Genetik [General Genetics]", Gustav Fischer Verlag, Stuttgart, 1986).

[0085] Possible mutations are transitions, transversions, insertions and deletions. Depending on the effect of the amino acid exchange on the enzyme activity, missense mutations or nonsense mutations are referred to. Insertions or deletions of at least one base pair (bp) in a gene lead to frame shift mutations, as a consequence of which incorrect amino acids are incorporated or translation is interrupted prematurely. Deletions of several codons typically lead to a complete loss of the enzyme activity. Instructions on generation of such mutations are prior art and can be found in known textbooks of genetics and molecular biology, such as e.g. the textbook by Knippers ("Molekulare Genetik [Molecular Genetics]", 6th edition, Georg Thieme Verlag, Stuttgart, Germany, 1995), that by Winnacker ("Gene und Klone [Genes and Clones]", VCH Verlagsgesellschaft, Weinheim, Germany, 1990) or that by Hagemann ("Allgemeine Genetik [General Genetics]", Gustav Fischer Verlag, Stuttgart, 1986).

[0086] A common method of mutating genes of *C. glutamicum* is the method of gene disruption and gene replacement described by Schwarzer and Puhler (Bio/Technology 9, 84-87 (1991)).

[0087] In the method of gene disruption a central part of the coding region of the gene of interest is cloned in a plasmid vector which can replicate in a host (typically *E. coli*), but not in *C. glutamicum*. Possible vectors are, for example, pSUP301 (Simon et al., Bio/Technology 1, 784-792 (1983)), pK18mob or pK19mob (Schafer et al., Gene 145, 69-73 (1994)), pK18mobsacB or pK19mobsacB (Jger et al., Journal of Bacteriology 174: 5462-65 (1992)), PGEM-T (Promega corporation, Madison, Wis., USA), pCR2.1-TOPO (Shuman (1994). Journal of Biological Chemistry 269:32678-84; U.S. Pat. No. 5,487,993), pCR.RTM.Blunt (Invitrogen, Groningen, Holland; Bernard et al., Journal of Molecular Biology, 234: 534-541 (1993)) or pEM1 (Schrumpf et al, 1991, Journal of Bacteriology 173:4510-4516). The plasmid vector which contains the central part of the coding region of the gene is then transferred into the desired strain of *C. glutamicum* by conjugation or transformation. The method of conjugation is described, for example, by Schfer et al. (Applied and Environmental Microbiology 60, 756-759 (1994)). Methods for transformation are described, for example, by Thierbach et al. (Applied Microbiology and Biotechnology 29, 356-362 (1988)), Dunican and Shivnan (Bio/Technology 7, 1067-1070 (1989)) and Tauch et al. (FEMS Microbiological Letters 123, 343-347 (1994)). After homologous recombination by means of a "cross-over" event, the coding region of the gene in question is interrupted by the vector sequence and two incomplete alleles are obtained, one lacking the 3' end and one lacking the 5' end. This method has been used, for example, by Fitzpatrick et al. (Applied Microbiology and Biotechnology 42, 575-580 (1994)) to eliminate the *recA* gene of *C. glutamicum*.

[0088] FIG. 1 shows by way of example the plasmid vector pCR2.1lysR3int, with the aid of which the *lysR3* gene can be disrupted or eliminated.

[0089] In the method of gene replacement, a mutation, such as e.g. a deletion, insertion or base exchange, is established in vitro in the gene of interest. The allele prepared is in turn cloned in a vector which is not replicative for *C. glutamicum* and this is then transferred into the desired host of *C. glutamicum* by transformation or conjugation. After homologous recombination by means of a first "cross-over" event which effects integration and a suitable second "cross-over" event which effects excision in the target gene or in the target sequence, the incorporation of the mutation or of the allele is achieved. This method was used, for example, by Peters-Wendisch et al. (Microbiology 144, 915-927 (1998)) to eliminate the *pyc* gene of *C. glutamicum* by a deletion.

[0090] A deletion, insertion or a base exchange can be incorporated into the *lysR3* gene in this manner.

[0091] In addition, it may be advantageous for the production of L-amino acids, in particular L-lysine and L-valine, to enhance, in particular to over-express, one or more enzymes of the particular biosynthesis pathway, of glycolysis, of anaplerosis, of the pentose phosphate cycle or of amino acid export, in addition to attenuation of the *lysR3* gene.

[0092] Thus, for example, for the preparation of L-lysine, at the same time one or more of the genes chosen from the group consisting of

[0093] the *dapA* gene which codes for dihydrodipicolinate synthase (EP-B 0 197 335),

[0094] the *eno* gene which codes for enolase (DE: 19947791.4),

[0095] the *zwf* gene which codes for the *zwf* gene product (JP-A-09224661),

[0096] the *pyc* gene which codes for pyruvate carboxylase (Peters-Wendisch et al. (Microbiology 144, 915-927 (1998))

[0097] the *lysE* gene which codes for lysine export (DE-A-195 48 222)

[0098] can be enhanced, in particular over-expressed.

[0099] It may furthermore be advantageous for the production of amino acids, in particular L-lysine, in addition to the attenuation of the *lysR3* gene, at the same time for one or more of the genes chosen from the group consisting of

[0100] the *pck* gene which codes for phosphoenol pyruvate carboxykinase (DE 199 50 409.1, DSM 13047),

[0101] the *pgi* gene which codes for glucose 6-phosphate isomerase (U.S. Ser. 09/396,478, DSM 12969),

[0102] the *poxB* gene which codes for pyruvate oxidase (DE:1995 1975.7, DSM 13114)

[0103] to be attenuated.

[0104] Thus, for example, for the production of L-valine

[0105] at the same time the *ilvBN* gene which codes for acetohydroxy-acid synthase (Keilhauer et al., (1993) Journal of Bacteriology 175: 5595-5603), or

[0106] at the same time the *ilvD* gene which codes for dihydroxy-acid dehydratase (Sahm and Eggeling (1999) Applied and Environmental Microbiology 65: 1973-1979), or

[0107] at the same time the mqo gene which codes for malate:quinone oxidoreductase (Molenaar et al., European Journal of Biochemistry 254, 395-403 (1998))

[0108] can be over-expressed.

[0109] In addition to attenuation of the lysR3 gene it may furthermore be advantageous, for the production of amino acids, in particular L-lysine and L-valine, to eliminate undesirable side reactions, (Nakayama: "Breeding of Amino Acid Producing Micro-organisms", in: Overproduction of Microbial Products, Krumphanzl, Sikyta, Vanek (eds.), Academic Press, London, UK, 1982).

[0110] The invention also provides the microorganisms prepared according to the invention, and these can be cultured continuously or discontinuously in the batch process (batch culture) or in the fed batch (feed process) or repeated fed batch process (repetitive feed process) for the purpose of production of L-amino acids, in particular L-lysine and L-valine. A summary of known culture methods are [sic] described in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik [Bioprocess Technology 1. Introduction to Bioprocess Technology (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen [Bioreactors and Peripheral Equipment] (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

[0111] The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981). Sugars and carbohydrates, such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as, for example, soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as, for example, palmitic acid, stearic acid and linoleic acid, alcohols, such as, for example, glycerol and ethanol, and organic acids, such as, for example, acetic acid, can be used as the source of carbon. These substance can be used individually or as a mixture.

[0112] Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.

[0113] Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus. The culture medium must furthermore comprise salts of metals, such as, for example, magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the abovementioned substances. Suitable precursors can moreover be added to the culture medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.

[0114] Basic compounds, such as sodium hydroxide, potassium hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH. Antifoams, such as, for example, fatty acid polyglycol esters, can be employed to control the development of foam. Suitable substances having a selective action, such as, for example, antibiotics, can be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as, for example, air, are introduced into the culture. The temperature of the culture is usually 20.degree. C. to 45.degree. C., and preferably 25.degree. C. to 40.degree. C. Culturing is continued until a maximum of the desired product has formed. This target is usually reached within 10 hours to 160 hours.

[0115] Methods for the determination of L-amino acids are known from the prior art. The analysis can thus be carried out, for example, as described by Spackman et al. (Analytical Chemistry, 30, (1958), 1190) by anion exchange chromatography with subsequent ninhydrin derivatization, or it can be carried out by reversed phase HPLC, for example as described by Lindroth et al. (Analytical Chemistry (1979) 51: 1167-1174).

[0116] The following microorganism has been deposited at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ=German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty:

[0117] Escherichia coli strain TOP10F/pCR2.1lysR3int as DSM 13618.

[0118] The process according to the invention is used for the fermentative preparation of amino acids, in particular L-lysine and L-valine.

[0119] The present invention is explained in more detail in the following with the aid of embodiment examples.

[0120] The isolation of plasmid DNA from Escherichia coli and all techniques of restriction, Klenow and alkaline phosphatase treatment were carried out by the method of Sambrook et al. (Molecular Cloning. A Laboratory Manual (1989) Cold Spring Harbour Laboratory Press, Cold Spring Harbor, N.Y., USA). Methods for transformation of Escherichia coli are also described in this handbook.

[0121] The composition of the usual nutrient media, such as LB or TY medium, can also be found in the handbook by Sambrook et al.

EXAMPLE 1

[0122] Preparation of a Genomic Cosmid Gene Library from C. glutamicum ATCC 13032

[0123] Chromosomal DNA from C. glutamicum ATCC 13032 was isolated as described by Täuch et al. (1995, Plasmid 33:168-179) and partly cleaved with the restriction enzyme Sau3AI (Amersham Pharmacia, Freiburg, Germany, Product Description Sau3AI, Code no. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim, Germany, Product Description SAP, Code no. 1758250). The DNA of the cosmid vector SuperCosI (Wahl et al., 1987, Proceedings of the National Academy of Sciences, USA 84:2160-2164), obtained from Stratagene (La Jolla, USA, Product Description SuperCosI Cosmid Vector Kit, Code no. 251301) was cleaved with the restriction enzyme XbaI (Amersham Pharmacia, Freiburg, Germany, Product Description XbaI, Code no. 27-0948-02) and likewise dephosphorylated with shrimp alkaline phosphatase.

[0124] The cosmid DNA was then cleaved with the restriction enzyme BamHI (Amersham Pharmacia, Freiburg, Germany, Product Description BamHI, Code no. 27-0868-04). The cosmid DNA treated in this manner was mixed with the treated ATCC13032 DNA and the batch was treated with T4 DNA ligase (Amersham Pharmacia, Freiburg, Germany, Product Description T4-DNA-Ligase, Code no.27-0870-04). The ligation mixture was then packed in phages with the aid of Gigapack II XL Packing Extract (Stratagene, La Jolla, USA, Product Description Gigapack II XL Packing Extract, Code no. 200217).

[0125] For infection of the *E. coli* strain NM554 (Raleigh et al. 1988, Nucleic Acid Res. 16:1563-1575) the cells were taken up in 10 mM MgSO₄ and mixed with an aliquot of the phage suspension. The infection and titring of the cosmid library were carried out as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), the cells being plated out on LB agar (Lennox, 1955, Virology, 1:190) +100 .mu.g/ml ampicillin. After incubation overnight at 37.degree. C., recombinant individual clones were selected.

EXAMPLE 2

[0126] Isolation and Sequencing of the *lysR3* Gene

[0127] The cosmid DNA of an individual colony was isolated with the Qiaprep Spin Miniprep Kit (Product No. 27106, Qiagen, Hilden, Germany) in accordance with the manufacturer's instructions and partly cleaved with the restriction enzyme *Sau3AI* (Amersham Pharmacia, Freiburg, Germany, Product Description *Sau3AI*, Product No. 27-0913-02). The DNA fragments were dephosphorylated with shrimp alkaline phosphatase (Roche Molecular Biochemicals, Mannheim, Germany, Product Description SAP, Product No. 1758250). After separation by gel electrophoresis, the cosmid fragments in the size range of 1500 to 2000 bp were isolated with the QiaExII Gel Extraction Kit (Product No. 20021, Qiagen, Hilden, Germany).

[0128] The DNA of the sequencing vector pZero-1, obtained from Invitrogen (Groningen, The Netherlands, Product Description Zero Background Cloning Kit, Product No. K2500-01) was cleaved with the restriction enzyme *BamHI* (Amersham Pharmacia, Freiburg, Germany, Product Description *BamHI*, Product No. 27-0868-04). The ligation of the cosmid fragments in the sequencing vector pZero-1 was carried out as described by Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor), the DNA mixture being incubated overnight with T4 ligase (Pharmacia Biotech, Freiburg, Germany). This ligation mixture was then electroporated (Tauch et al. 1994, FEMS Microbiol Letters, 123:343-7) into the *E. coli* strain DH5AMCR (Grant, 1990, Proceedings of the National Academy of Sciences, U.S.A., 87:4645-4649) and plated out on LB agar (Lennox, 1955, Virology, 1:190) with 50 .mu.g/ml zeocin.

[0129] The plasmid preparation of the recombinant clones was carried out with Biorobot 9600 (Product No. 900200, Qiagen, Hilden, Germany). The sequencing was carried out by the dideoxy chain termination method of Sanger et al. (1977, Proceedings of the National Academies of Sciences, U.S.A., 74:5463-5467) with modifications according to Zimmermann et al. (1990, Nucleic Acids Research, 18:1067). The "RR dRhodamin Terminator Cycle Sequencing Kit" from PE Applied Biosystems (Product No. 403044, Weiterstadt, Germany) was used. The separation by gel electrophoresis and analysis of the sequencing reaction were carried out in a "Rotiphoresis NF Acrylamide/Bisacrylamide" Gel (29:1) (Product No. A124.1, Roth, Karlsruhe, Germany) with the "ABI Prism 377" sequencer from PE Applied Biosystems (Weiterstadt, Germany).

[0130] The raw sequence data obtained were then processed using the Staden program package (1986, Nucleic Acids Research, 14:217-231) version 97-0. The individual sequences of the pZero derivatives were assembled to a continuous contig. The computer-assisted coding region analysis [sic] were prepared with the XNIP program (Staden, 1986, Nucleic Acids Research, 14:217-231). Further analyses were carried out with the "BLAST search program" (Altschul et al., 1997, Nucleic Acids Research, 25:3389-3402) against the non-redundant databank of the "National Center for Biotechnology Information" (NCBI, Bethesda, Md., USA).

[0131] The resulting nucleotide sequence is shown in SEQ ID No. 1. Analysis of the nucleotide sequence showed an open reading frame of 633 base pairs, which was called the *lysR3* gene. The *lysR3* gene codes for a polypeptide of 210 amino acids.

EXAMPLE 3

[0132] Preparation of an Integration Vector for Integration Mutagenesis of the *lysR3* Gene

[0133] From the strain ATCC 13032, chromosomal DNA was isolated by the method of Eikmanns et al. (Microbiology 140: 1817-1828 (1994)). On the basis of the sequence of the *lysR3* gene known for *C. glutamicum* from example 2, the following oligonucleotides were chosen for the polymerase chain reaction:

[0134] *lysR3*intA:

[0135] 5'GAT GTG GTG TTG ATG GAT CT 3' (SEQ ID No. 4)

[0136] *lysR3*intB:

[0137] 5'TCA ATT TCT CTG GCA CTG AG 3' (SEQ ID No. 5)

[0138] The primers shown were synthesized by MWG Biotech (Ebersberg, Germany) and the PCR reaction was carried out by the standard PCR method of Innis et al. (PCR protocols. A guide to methods and applications, 1990, Academic Press) with Pwo-Polymerase from Boehringer. With the aid of the polymerase chain reaction, an internal fragment of the *lysR3* gene 323 bp in size was isolated, this being shown in SEQ ID No. 3.

[0139] The amplified DNA fragment was ligated with the TOPO TA Cloning Kit from Invitrogen Corporation (Carlsbad, Calif., USA; Catalogue Number K4500-01) in the vector pCR2.1-TOPO (Mead et al. (1991) Bio/Technology 9:657-663).

[0140] The *E. coli* strain TOP10F was then electroporated with the ligation batch (Hanahan, In: DNA cloning. A practical approach. Vol. I, IRL-Press, Oxford, Washington D.C., USA, 1985). Selection for plasmid-carrying cells was made by plating out the transformation batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2.sup.nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), which had been supplemented with 25 mg/l kanamycin. Plasmid DNA was isolated from a transformant with the aid of the Qiaprep Spin Miniprep Kit from Qiagen and checked by restriction with the restriction enzyme *EcoRI* and subsequent agarose gel electrophoresis (0.8%). The plasmid was called pCR2.1*lysR3*int.

EXAMPLE 4

[0141] Integration Mutagenesis of the *lysR3* Gene in the Lysine Producer DSM 5715 and in the Valine Producer FERM BP-1763

[0142] The vector pCR2.1*lysR3*int mentioned in example 3 was electroporated by the electroporation method of Tauch et al. (FEMS Microbiological Letters, 123:343-347 (1994)) into *Corynebacterium glutamicum* DSM 5715 and *Brevibacterium lactofermentum* FERM BP-1763. The strain DSM 5715 is an AEC-resistant lysine producer. The strain FERM BP-1763 is a valine producer in need of isoleucine and methionine. The vector pCR2.1*lysR3*int cannot replicate independently in DSM 5715 or FERM BP-1763 and is retained in the cell only if it has integrated into the

chromosome of DSM 5715 or FERM BP-1763. Selection of clones with pCR2.1lysR3int integrated into the chromosome was carried out by plating out the electroporation batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2.sup.nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.), which had been supplemented with 15 mg/l kanamycin.

[0143] For detection of the integration, the lysR3int fragment was labelled with the Dig hybridization kit from Boehringer by the method of "The DIG System Users Guide for Filter Hybridization" of Boehringer Mannheim GmbH (Mannheim, Germany, 1993). Chromosomal DNA of a potential integrant was isolated by the method of Eikmanns et al. (Microbiology 140: 1817-1828 (1994)) and in each case cleaved with the restriction enzymes Sall, SacI and HindIII. The fragments formed were separated by agarose gel electrophoresis and hybridized at 68.degree. C. with the Dig hybridization [sic] kit from Boehringer. The plasmid pCR2.1lysR3int mentioned in example 3 had been inserted into the chromosome of DSM5715 and FERM BP-1763 within the chromosomal lysR3 gene. The strains were called DSM5715::pCR2.1lysR3int and FERM BP-1763::pCR2.1lysR3int.

EXAMPLE 5

[0144] Preparation of L-lysine and L-valine

[0145] The *C. glutamicum* and *B. lactofermentum* strains DSM5715::pCR2.1lysR3int and FERM BP-1763::pCR2.1lysR3int obtained in example 4 were cultured in a nutrient medium suitable for the production of L-lysine and L-valine and the L-lysine and L-valine content in the culture supernatant was determined.

[0146] For this, the strains were first incubated on an agar plate with the corresponding antibiotic (brain-heart agar with kanamycin (25 mg/l) for 24 hours at 33.degree. C. Starting from this agar plate culture, a preculture was seeded (10 ml medium in a 100 ml conical flask). The complete medium CgIII was used as the medium for the preculture.

1 Medium Cg III NaCl 2.5 g/l Bacto-Peptone 10 g/l Bacto-Yeast extract 10 g/l Glucose (autoclaved separately) 2% (w/v) The pH was brought to pH 7.4

[0147] Kanamycin (25 mg/l) was added to this. The preculture was incubated for 24 hours at 33.degree. C. at 240 rpm on a shaking machine. A main culture was seeded from this preculture such that the initial OD (660 nm) of the main culture was 0.1 OD. Medium MM was used for the main culture.

2 Medium MM CSL (corn steep liquor) 5 g/l MOPS 20 g/l Glucose (autoclaved separately) 50 g/l Salts: (NH.sub.4).sub.2SO.sub.4) 25 g/l KH.sub.2PO.sub.4 0.1 g/l MgSO.sub.4 * 7 H.sub.2O 1.0 g/l CaCl.sub.2 * 2 H.sub.2O 10 mg/l FeSO.sub.4 * 7 H.sub.2O 10 mg/l MnSO.sub.4 * H.sub.2O 5.0 mg/l Biotin (sterile-filtered) 0.3 mg/l Thiamine * HCl (sterile-filtered) 0.2 mg/l CaCO.sub.3 25 g/l

[0148] The CSL, MOPS and the salt solution are brought to pH 7 with aqueous ammonia and autoclaved. The sterile substrate and vitamin solutions are then added, as well as the CaCO.sub.3 autoclaved in the dry state. For culturing of DSM 5715, 0.1 g/l leucine was additionally added to the medium. For culturing of FERM BP-1763, 0.1 g/l isoleucine and 0.1 g/l methionine were additionally added to the medium. Culturing is carried out in a 10 ml volume in a 100 ml conical flask with baffles. Kanamycin (25 mg/l) was added.

[0149] Culturing was carried out at 33.degree. C. and 80% atmospheric humidity.

[0150] After 72 hours, the OD was determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Munich). The amount of L-lysine and of L-valine formed was determined with an amino acid analyzer from Eppendorf-BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivatization with ninhydrin detection.

[0151] The results of the experiment are shown in tables 1 and 2.

3TABLE 1 Lysine HCl Strain OD (660) g/2 DSM5715 7.5 13.01 DSM5715::pCR2.1lysR3int 7.6 15.04

[0152]

4TABLE 2 Valine Strain OD (660) g/l FERM BP-1763 12.1 7.49 FERM BP- 12.5 8.67 1763::pCR2.1lysR3int

[0153] The abbreviations and designations used have the following meaning.

5 KmR: Kanamycin resistance gene EcoRI: cleavage site of the restriction enzyme EcoRI lysR3int: Internal fragment of the lysR3 gene ColE1 ori: Replication origin of the plasmid ColE1

[0154] Obviously, numerous modifications and variations on the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.